Incyte Corp said that it would stop a mid-stage study on
its combination treatment after it failed to prove to be sufficiently
effective to treat metastatic colorectal cancer.
The results cast a shadow on the prospects of the drug, Jakafi, which
is also being studied in a late-stage trial to treat advanced
pancreatic cancer.
Jakafi is an FDA-approved drug to treat people with bone marrow
disorders such as polycythemia vera and blood disorders including
myelofibrosis.
Incyte was testing Jakafi in combination with Bayer AG's Regorafenib
to treat metastatic colorectal cancer, in which diseased cells break
away from the colon or rectum and spread to form tumors on other organs.
No comments:
Post a Comment